G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointments of Jack Bailey to its Board of Directors and Soma Gupta as its Chief Commercial Officer (CCO). “We are pleased to welcome Jack and Soma, and their breadth of commercial experience, as we work toward the approval of trilaciclib in small cell lung cancer,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Drug Application (NDA) submission for trilaciclib in small cell lung cancer on track for 2Q20Trilaciclib selected for inclusion in I-SPY 2 breast cancer trialRintodestrant.
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.
On today's call, Mark Velleca, Chief Executive Officer; Raj Malik, Chief Medical Officer and Senior Vice President of R&D and Jen Moses, Chief Financial Officer will provide an overview of the quarter with Q&A to follow. Before we begin, I would like to remind you that this call will include forward-looking statements based on current expectations.
- Trilaciclib significantly reduced myelosuppression and need for related supportive care interventions for patients with small cell lung cancer (SCLC) receiving chemotherapy -.
There's a growing consensus that the Triangle is not only strapped for the venture capital needed to make innovative ideas coming out of local universities work, but it is also severely lacking in the kind of corporate leadership needed to guide innovation to successful commercial companies.
Q3 2019 G1 Therapeutics Inc Earnings Call
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.
RESEARCH TRIANGLE PARK, N.C., April 29, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the first quarter ended March 31, 2020. “We have activated business continuity plans in response to the COVID-19 pandemic to ensure we can advance therapies that patients with cancer, their families, and healthcare providers are counting on to improve outcomes, and also taken actions to safeguard the well-being of our employees,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer.
RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik,.
Quantum Leap Healthcare Collaborative™ and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy, in a new randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibitor lerociclib in combination with fulvestrant for the treatment of estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. Updated findings presented during a poster session (P1-19-17) at the 2019 San Antonio Breast Cancer Symposium (SABCS) showed lerociclib, dosed without a drug holiday, has a differentiated safety and tolerability profile than observed in clinical trials with currently marketed CDK4/6 inhibitors.
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.
RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.
Global concerns over the spread of the novel coronavirus rocked stock markets on Monday. The spread of COVID-19 has been a major economic punch felt around the globe, and it's impacting production at Triangle firms – from Lenovo to Cree.
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will present corporate.
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.
RESEARCH TRIANGLE PARK, N.C., April 07, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.